Introduction

Peripheral neuropathic pain is defined as “pain caused by a lesion or disease of the peripheral somatosensory nervous system” [1, 2]. Traumatic injuries, certain medications such as cytotoxic agents, and systemic diseases such as diabetes mellitus are among the most common causes of peripheral neuropathic pain. Allodynia (pain response to normally non-painful stimulus) and hyperalgesia (augmented pain response to normally painful stimulus) are prominent clinical symptoms associated with neuropathic patients [1, 3, 4]. Current pharmacological treatments for neuropathic pain are typically insufficient at reducing pain symptoms. Even most of the powerful painkillers like morphine and other opioid drugs are inadequate; they are generally effective at higher doses when their adverse effects are seen. In general, antidepressants (e.g., amitriptyline and nortriptyline) and some anticonvulsant drugs (e.g., gabapentin, pregabalin) are recommended for first-line treatment of neuropathic pain; however, it is clear that there is a lack of specific medications that effectively treat this indication [5–7].

Serotonin (5-hydroxytryptamine; 5-HT) is a biogenic amine extensively distributed both in peripheral and central nervous systems. Serotonin contributes to pain modulation by interacting with
different 5-HT receptors [8–10]. Up to now, 7 families of 5-HT receptors (5-HT1–5-HT7) have been identified. At the periphery, 5-HT has been shown to exert pronociceptive actions mediated via 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT4, 5-HT6, and 5-HT7 receptors [10–13]. On the contrary, its spinal effects appear to be more complicated than peripheral effects. 5-HT exerts antinociception at lower doses, whereas it produces pronociceptive effects at higher doses; physiologic or pathophysiologic status of the animal (e.g., neuropathic pain, inflammation) may also have an impact on the net spinal outcome. It is generally accepted that activation of spinal 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F and 5-HT5A receptors reduce nociception, while spinal 5-HT2, 5-HT3, 5-HT4, 5-HT6 and 5-HT7 receptors augment nociception when activated [10, 11, 14–17].

5-HT6 receptor subfamily is one of the least known 5-HT receptor subtypes. They are positively coupled to adenylate cyclase, which in turn produces cyclic AMP, and may exert an excitatory action on neuronal activity [18]. 5-HT6 receptors are exclusively localized in pain-related areas, such as periaqueductal gray, spinal cord and dorsal root ganglion [19], indicating that these receptors may play a pivotal role in pain modulation at different levels of central nervous system. 5-HT6 receptors have been shown to be pronociceptive in formalin-induced pain [20], and 5-HT6 antagonists have been shown to reduce nociceptive behavior in the same test [21]. Both peripheral and spinal 5-HT6 receptors have been shown to play role in the development and maintenance of secondary mechanical allodynia and hyperalgesia [12, 14]. Recent studies on neuropathic pain states suggest that 5-HT6 receptor antagonists attenuate neuropathic pain behaviors in spinal nerve ligated rats [22–24]; however, there are also contradictory results indicating that 5-HT6 receptor antagonists do not exert antinociception in neuropathic rats [25].

Taking into consideration all these data on the effect of 5-HT6 receptors and their antagonists on neuropathic pain conditions, we aimed to investigate the effect of systemically and spinally administered 5-HT6 receptor antagonists on thermal hyperalgesia, and to determine spinal lumbar serotonin and 5-HT6 receptor levels during development of diabetic neuropathy in mice.

Materials and Methods

Animals and ethics

Male Balb/c mice (Center of the Laboratory Animals, Trakya University) weighing 20–30 g (n = 8 for each group) were used through these experiments. Animals were housed under a 12–12 h light/dark cycle at a constant temperature of 21 ± 2 °C and had free access to food and water and food. All experiments were carried out between 10:00 and 17:00. The experiments were conducted in strict accordance with “Guide for the Care and Use of Laboratory Animals” published by National Academy of Sciences and the experimental protocols were approved by the ethics committee of Trakya University.

Assessment of antinociception and motor coordination

The nociceptive response was assessed using a standardized cold/hot plate apparatus (Ugo Basile, Comerio, Italy). To conduct the hot plate test, mice were put on a heated surface kept at a temperature of 55 ± 0.1 °C, and response latencies for jumping or paw licking were documented. To prevent tissue damage, a cut-off time of 25 s was set. Test latencies in the hot plate test were converted to the percentage of the maximal possible effect (%MPE) according to the formula: 

\[ \%MPE = \left( \frac{\text{postdrug latency} - \text{baseline latency}}{\text{cut-off time} - \text{baseline latency}} \right) \times 100 \]

The changes in locomotor function after intrathecal injections and in diabetic mice were evaluated using a rotarod apparatus (Commat, Ankara, Turkey). The animals were placed on the apparatus and allowed to explore it during 5 min. Then, mice were placed on the rod rotating at 16 rpm and the performance time until the mice fell from the rod were recorded. A cut-off time of 180 s were set before the assessments [27].

Study design and drugs

Streptozocin (STZ, 150 mg/kg, i.p.), freshly prepared in 0.1 N citrate buffer at pH 4.5, was administered to induce diabetes. The development of diabetes was confirmed 1 week after STZ injection by measurement of tail-vein plasma glucose levels, using IME-DC (Germany) test strips. Mice were considered diabetic when blood glucose levels were at least 200 mg/dl [28]. Thermal thresholds for the hot plate tests were determined on days 5, 9 and 15 after injection of STZ.

To determine the effect of 5-HT6 receptor blockade on thermal hyperalgesia in diabetic mice, different doses of the 5-HT6 antagonist, SB-258585, was given systemically (3, 10, 30 mg/kg, i.p.) and intrathecally (0.01, 0.1, 1 nmol/mouse/i.t.) on day 15 after induction of diabetes. Thermal thresholds for the hot plate tests were investigated before and 30, 60, 90 and 120 min after the injections. Intrathecal injections were made using a widely accepted technique [29]. Additionally, on 7th and 15th days of diabetes, a different group of drug-naive mice were euthanized and lumbar spinal cord was extracted to examine serotonin and 5-HT6 receptor levels, using LC/MS/MS and Western blot analyses, respectively.

Streptozocin and SB-258585, a 5-HT6 receptor antagonist, were purchased from Sigma-Aldrich (St Louis, MO, USA). SB-258585 was given in 20 % DMSO, 1 % Tween 80, 1 % ethanol, and 78 % saline. Doses and treatment times of STZ and SB-258585 were selected from previous studies [12, 14, 20, 24].

LC/MS/MS

Frozen mice brain tissue samples were placed in a 1.5 mL polypropylene tube and an extraction solution (%1 formic acid in water, 10 dilution factor) was added. The mixture was vortexed for 1 min and sonicated for 10 min at 45 °C. After sonication the mixture was centrifuged for 5 min, at 9000 rpm. The supernatant was transferred to micro-vial and a 3 μL sample was injected into the LC–MS–MS system for analysis.

Chromatography was performed on an Agilent 1260 infinity LC system (Agilent Technology, Waldbronn, Germany), consisting of quaternary pumps, an autosampler, a vacuum degasser and a column compartment. Separation was on a reversed phase Agilent Zorbax C8 column (3.0 × 150 mm 3.5micron). The mobile phase A consisted of 5 mM ammonium formate and 0.1 % formic acid in water and mobile phase B consisted of 90 % formic acid in acetonitrile. The flow rate was 0.5 mL min−1 and the column temperatures was 35 °C. The injection volume was 3 μL. The analysis time was 429
11 min for each run. The elution strength usually increases with time, where the gradient starts at 3 %B and rise up 97 %B at 4 min and return 3 %B at 7 min. Mass spectra was obtained with an Agilent 6460 triple quadrupole mass spectrometer equipped with an Electrospray ionization (ESI) source, under the control of the MassHaunter software (version 8.05.00). The mass spectrometer was operated in positive-ion, MRM mode. The source temperature of the sheath gas was adjusted to 400 °C and nebulizer rate was 45 psi. The gas flow was 10 L min⁻¹ and the capillary voltage was 2,500 V. Collision energy was 4 V for 160.1 and 30 V for 114.9. Singly charged precursor-product ion transitions were monitored at m/z 177.0 → 160.1 and 177.0 → 114.9 (serotonin). The dwell time was 100 ms for each product ion. The linearity fitted well over the range of 1.0–100 ng mL⁻¹ for 5 different concentration and serotonin LOD and LOQ values are 0.23 ng mL⁻¹ and 0.69 ng mL⁻¹, respectively. The linearity was R² 0.99931. The recoveries were carried out spiked real sample and 88.9 % was obtained for spiked 25 ng mL⁻¹ and 94.2 % for spiked 50 ng mL⁻¹.

Western blot analysis
Western blot analyses were performed as described previously [30, 31] Tissue samples were homogenized in tissue extraction buffer (Santa cruz biotechnology, Finnell Street, Dallas, USA). Total protein concentration was measured using Qubit 2.0 fluorometer (Invitrogen, Carlsbad, CA, USA). 20 µL samples were loaded into NuPage Novex 4–12 % Bis-Tris gel (Life Technologies, Invitrogen, Carlsbad, CA, USA) and subjected to vertical electrophoresis. Then, samples were transferred to nitrocellulose membrane using the iblot semi dry blotting system (The iblotTM Gell Transfer Stack, Nitrocellulose, Invitrogen). The membrane was blocked with blocking solution for 30 min to reduce nonspecific binding (Western Blotting procedure). Afterwards, the membranes were incubated overnight at 4 °C with rabbit polyclonal 5-HT₆ antibody (1 : 500 dilution in blocking solution, ab103016) and rabbit polyclonal anti-β-actin antibody (1 : 1000 dilution in blocking solution, Novus Biologicals). The membrane was washed 3 times for 10 min with wash buffer and then incubated with secondary antibody for 30 min (Western Blotting Chemiluminescent Western Blot Immunodetection Kit Antirabbit; Invitrogen). Following washing 3 times for 10 min with wash buffer, the protein was visualized by Chemidoc™ MP Imaging System (Universal Hood 3; Bio-Rad, Hercules, CA, USA) with enhanced chemiluminescence substrate (Invitrogen). Immunoblot bands for 5-HT₆ and β-actin were quantified using an Image J 1.48 v program (Wayne Rasband, National Institutes of Health, Bethesda, MD, USA). The ratio of the density of 5-HT₆ to β-actin was calculated for each sample.

Statistical analysis
Data from the hot-plate experiment were evaluated using 2-way analysis of variance (ANOVA), followed by Bonferroni t test. Differences in lumbar dorsal spinal cord 5-HT levels and 5-HT₆ receptor expression were compared using unpaired t-test. P < 0.05 was considered to be significant for all experiments. All data are expressed as mean ± SEM.

Results

Effects of the 5-HT₆ antagonist on thermal hyperalgesia in diabetic mice

Starting from day 5 after induction of diabetes, significant thermal hyperalgesia was observed (2-way ANOVA followed by Bonferroni t test, * P < 0.0001, ▶ Fig. 1). On day 15, systemic administration of the 5-HT₆ receptor antagonist SB-258585 (3, 10, 30 mg/kg, i.p.) decreased thermal hyperalgesia in diabetic mice (2-way ANOVA followed by Bonferroni t test, ▶ Fig. 2a). 3 mg/kg and 10 mg/kg doses of SB-258585 was effective at 60, 90 and 120th mins, whereas treatment with 30 mg/kg of SB-258585 was efficacious at 30, 60 and 90 mins. SB-258585 (0.01, 0.1, 1 nmol/mouse) had no effect on thermal hyperalgesia when administered intrathecally (2-way ANOVA followed by Bonferroni t test, ▶ Fig. 2b).

Serotonin levels and 5-HT₆ receptor expression in the lumbar spinal cord

Spinal serotonin levels did not change in diabetic mice; it is worth mentioning that there was a modest but statistically insignificant increase on day 15 of diabetes (▶ Fig. 3, unpaired t-test). Lumbar spinal 5-HT₆ receptor levels were significantly decreased both in 7th (unpaired t-test, * P < 0.05) and 15th (unpaired t-test, ** P < 0.0001) days after STZ injection (▶ Fig. 4).

Effects of diabetes and intrathecal injections on locomotor activity

Neither diabetes nor i.t. injection had any effect on motor coordination (data not shown).

Discussion

The 5-HT₆ receptor is a 7-transmembrane receptor positively coupled to adenylyl cyclase. Its activation leads to stimulation of adenylyl cyclase and may produce an excitatory effect on neuronal activity [18]. When released, 5-HT may exert opposite (pronociceptive or antinociceptive) actions depending upon the 5-HT receptor subtype. Although there is little research on the role 5-HT₆ receptors in nociception, these receptors appear to mediate pronociceptive effects both at the periphery and the spinal cord.
First studies on this subject indicated that pharmacological blockade of 5-HT$_6$ receptors reduce formalin-induced nociceptive behavior [21], and that both local peripheral and spinal 5-HT$_6$ receptors play a pronociceptive role in formalin induced pain [20]. Then, both peripheral and spinal 5-HT$_6$ receptors have been shown to play roles in development and maintenance of formalin-induced secondary mechanical allodynia and hyperalgesia [12, 14]. The same group also demonstrated that 5-HT$_6$ receptors takes part in peripheral pronociceptive but not in spinal antinociceptive effects of fluoxetine, a selective serotonin re-uptake inhibitor [11].

All of the above-mentioned observations point to the pronociceptive feature of 5-HT$_6$ receptors both at the periphery and the spinal cord; however, in case of neuropathic pain there are contradictory findings. In the rat spinal nerve ligation model of neuropathic pain, oral administration of compounds that exert potent 5-HT$_6$ antagonistic effects exhibited stronger potency than gabapentin against cold allodynia, whereas a diminished pain inhibitory effect was observed against mechanical allodynia [22]. Similar oral compounds showing good 5-HT$_6$ inhibitory activity confirmed these findings displaying anti-allodynic effects in spinal nerve ligated neuropathic rats, but this time mechanical allodynia alleviating effect was superior to cold allodynia [23]. On the contrary, 5-HT$_6$ antagonists had no effect on mechanical allodynia in neuropathic rats, but only improved analgesic effects of gabapentinoids, such as gabapentin and pregabalin [25]. Different from these oral administrations, intrathecal injection of 5-HT$_6$ antagonists decreased tactile allodynia in a dose-dependent manner and 5-HT$_6$ receptors have been indicated to contribute to maintenance of neuropathic pain in rat [24]. Other than these researches on allodynia, we show for the first time that systemic, but not intrathecal, 5-HT$_6$ antagonist reduces ther-

---

**Fig. 2** Time course of the effects of systemic (3, 10, 30 mg/kg) and intrathecal (0.01, 0.1, 1 nmol/mouse) administrations of the 5-HT$_6$ receptor antagonist SB-258585 on thermal hyperalgesia in diabetic mice on day 15 after streptozocin injection (2-way analysis of variance followed by Bonferroni t test, * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001, vs. control group.

**Fig. 3** LC/MS/MS analysis of lumbar dorsal spinal cord for serotonin content in control and diabetic mice on days 7 and 15 after respective vehicle or streptozocin injections. No significant change was observed (unpaired t-test).

**Fig. 4** Western blot analysis of lumbar dorsal spinal cord for 5-HT$_6$ expression in control and diabetic mice on days 7 and 15 after respective vehicle or streptozocin injections (unpaired t-test, * P<0.05, ** P<0.0001 vs. control group).
nal hyperalgesia in diabetic neuropathy. It should be taken into consideration that peripheral sensitization and central changes contribute to generation and maintenance of different subtypes of allodynia and hyperalgesia with separate mechanisms [3]; moreover, allodynia and hyperalgesia of nerve injury-induced neuropathic animals may not share the same etiology with allodynia and hyperalgesia of STZ-induced diabetic animals [32, 33].

Pain stimuli activates descending serotonergic pathways and in turn release of 5-HT at the spinal cord, which is pivotal for spinal nociceptive transmission [9, 34]. Then, 5-HT can exert facilitatory or inhibitory effects depending basically on the spinal 5-HT receptor subtype and several other reasons. Both nerve injury and diabetes have shown to increase 5-HT content at the spinal cord, which may account for enhanced pain during these neuropathic pain states [9, 34, 35]. Our results indicating that spinal 5-HT levels do not change during development of hyperalgesia appear to be contradictory to findings of Morgado et al. [35], but they demonstrated higher levels of 5-HT 4 weeks after induction of diabetes; our results also point to a slight increase in spinal 5-HT levels on day 15 which may be an indication of higher 5-HT levels after 4 weeks.

Spinal nerve injury leads to a loss of descending serotonergic neurons [36], whereas it did not modify expression of spinal 5-HT6 receptors [35]. Unlike nerve injury-induced neuropathy, we found that expression of 5-HT6 receptors were significantly attenuated in diabetes-induced neuropathy; this can be the reason of inadequate efficacy of the intrathecally administered 5-HT6 antagonist against thermal hyperalgesia in diabetic rats. In conclusion, our data demonstrate that systemic, but not spinal, blockade of 5-HT6 receptors attenuate thermal hyperalgesia in diabetic mice and propose that 5-HT6 receptor antagonists may have utility in the pharmacotherapy of diabetic neuropathy.

Acknowledgement

This work was supported by a grant from Trakya University Research Council (TUBAP-2016/43). We thank K. Duvan-Aydemir for her technical support for behavioral & western blot analysis.

Conflict of Interest

The authors have no conflicts of interests to report.

References


